Top Markets
#1 Pleasing Gold Pleasing Gold +601.59%
#2 Islamic Coin Islamic Coin +154.12%
#3 PulseChain PulseChain +52.83%
#4 BOOK OF MEME BOOK OF MEME +41.48%
#5 DogBull DogBull +36.81%
#6 Neiro Neiro +24.76%
#7 Nockchain Nockchain +22.48%
#8 ORDI ORDI +19.01%
#9 SkyAI SkyAI +16.82%
#10 Monad Monad +16.62%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Grace Therapeutics, Inc. Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCE
Rank in Stocks #27034
Grace Therapeutics, Inc. specializes in the creation and commercialization of... Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Share Price
$2.18
Last synced: 2026-08-19
Market Cap
$35.55M
Change (1 day)
2.57%
Change (1 year)
-33.19%
Country
US
Trade Grace Therapeutics, Inc. (GRCE)

Category

Healthcare
Revenue for Grace Therapeutics, Inc. (GRCE)
Revenue in Aug 2026 TTM: 0
According to Grace Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Grace Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH